JPWO2019156216A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019156216A5 JPWO2019156216A5 JP2019571167A JP2019571167A JPWO2019156216A5 JP WO2019156216 A5 JPWO2019156216 A5 JP WO2019156216A5 JP 2019571167 A JP2019571167 A JP 2019571167A JP 2019571167 A JP2019571167 A JP 2019571167A JP WO2019156216 A5 JPWO2019156216 A5 JP WO2019156216A5
- Authority
- JP
- Japan
- Prior art keywords
- cardiomyocytes
- cardiomyocyte
- promoting agent
- cell cycle
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 60
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 230000022131 cell cycle Effects 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 230000035519 G0 Phase Effects 0.000 claims description 2
- 230000010190 G1 phase Effects 0.000 claims description 2
- 230000010337 G2 phase Effects 0.000 claims description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000027902 cell growth involved in cardiac muscle cell development Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 7
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018021729 | 2018-02-09 | ||
| JP2018021729 | 2018-02-09 | ||
| PCT/JP2019/004631 WO2019156216A1 (ja) | 2018-02-09 | 2019-02-08 | 心筋細胞増殖促進剤及びその利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2019156216A1 JPWO2019156216A1 (ja) | 2021-03-11 |
| JPWO2019156216A5 true JPWO2019156216A5 (https=) | 2022-02-15 |
| JP7427223B2 JP7427223B2 (ja) | 2024-02-05 |
Family
ID=67549470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571167A Active JP7427223B2 (ja) | 2018-02-09 | 2019-02-08 | 心筋細胞増殖促進剤及びその利用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20210363486A1 (https=) |
| JP (1) | JP7427223B2 (https=) |
| WO (1) | WO2019156216A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021096998A1 (en) * | 2019-11-11 | 2021-05-20 | Atsuo Ochi | Method and a kit to reprogram somatic cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008114544A1 (ja) * | 2007-03-16 | 2008-09-25 | Tokyo Metropolitan Organization For Medical Research | 細胞周期可視化プローブ |
| BRPI0810949A2 (pt) * | 2007-05-29 | 2015-10-27 | Christopher B Reid | "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método" |
| CA2785966C (en) * | 2009-12-29 | 2020-10-27 | Takeda Pharmaceutical Company Limited | Method for manufacturing pancreatic-hormone-producing cells |
| WO2015045333A1 (ja) * | 2013-09-25 | 2015-04-02 | シミックホールディングス株式会社 | 心筋細胞増殖誘導剤及びこれを含有する医薬組成物、並びに心筋細胞の製造方法 |
| EP3474868A4 (en) * | 2016-06-27 | 2020-07-29 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | MODIFIED GLYCOPROTEINS. |
-
2019
- 2019-02-08 US US16/968,125 patent/US20210363486A1/en not_active Abandoned
- 2019-02-08 JP JP2019571167A patent/JP7427223B2/ja active Active
- 2019-02-08 WO PCT/JP2019/004631 patent/WO2019156216A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kanno et al. | Nitric oxide facilitates cardiomyogenesis in mouse embryonic stem cells | |
| KR102598772B1 (ko) | 상피 세포의 생체외 증식 | |
| TWI720333B (zh) | 多能性幹細胞的製備方法、使用該製備方法而製備出多能性幹細胞、改善劑、以及該多能性幹細胞之分化誘導方法 | |
| Bi et al. | Identification of human temporomandibular joint fibrocartilage stem cells with distinct chondrogenic capacity | |
| WO2007070964A1 (en) | Direct differentiation of cardiomyocytes from human embryonic stem cells | |
| JP2015527886A (ja) | 多能性幹細胞の心室心筋細胞へのインビトロでの分化を誘導するための方法 | |
| S Choudhery et al. | Utility of cryopreserved umbilical cord tissue for regenerative medicine | |
| CN109689858B (zh) | 用于产生具有体内血管形成能力的中胚层和/或内皮集落形成细胞样细胞的方法 | |
| CN102105789A (zh) | 人骨骼肌中的褐色脂肪细胞祖细胞 | |
| KR20210098431A (ko) | 세포-유래 소포를 포함하는 조성물 및 그의 용도 | |
| Ennis et al. | Isolation, characterization, and differentiation of human umbilical cord perivascular cells (HUCPVCs) | |
| Lewallen et al. | Osteogenic potential of human adipose-tissue-derived mesenchymal stromal cells cultured on 3D-printed porous structured titanium | |
| JP2008523823A (ja) | ヒト胚性幹細胞の分化ならびにそれに由来する心筋細胞および心筋前駆細胞 | |
| Mohamad-Fauzi et al. | Impact of source tissue and ex vivo expansion on the characterization of goat mesenchymal stem cells | |
| JP2013502219A (ja) | ヒト皮膚外植片培養系及びその使用 | |
| Karoubi et al. | Identification of mesenchymal stromal cells in human lung parenchyma capable of differentiating into aquaporin 5-expressing cells | |
| Lange et al. | Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells | |
| Bharti et al. | Differentiation potential of different regions-derived same donor human Wharton’s jelly mesenchymal stem cells into functional smooth muscle-like cells | |
| Shi et al. | The effect of extended passaging on the phenotype and osteogenic potential of human umbilical cord mesenchymal stem cells | |
| US11834679B2 (en) | Method for producing cardiomyocytes | |
| JPWO2019156216A5 (https=) | ||
| JP5940147B2 (ja) | 心筋指向性細胞を含む細胞製剤 | |
| Mu et al. | Slow-adhering stem cells derived from injured skeletal muscle have improved regenerative capacity | |
| KR20160018668A (ko) | Pdgf를 함유하는 ds 세포용 무혈청 배지 | |
| JP7427223B2 (ja) | 心筋細胞増殖促進剤及びその利用 |